RadCommonsUMA INICIATIVA DA laudos.ai RESEARCH
Ann Arbor · Oncologia
Sistemas/Oncologia

Ann Arbor staging of lymphoma (Cotswolds/Lugano-modified)

vigente

Stages lymphoma by anatomic distribution of nodal and extranodal involvement, with A/B/E/S/X modifiers.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
IIIIIIIV

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
Lymphoma staging consensus
Versão
current
Ano
1971
Família
algoritmo
Tipo de lógica
flat
Modalidade
CT, PET
Fonte primária
Ann Arbor staging
Última verificação
2026-06-26
Última checagem
2026-06-26

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Mostrar a lógica estruturada (JSON)
{
  "categories": [
    "I",
    "II",
    "III",
    "IV"
  ]
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
I
Stage I
Disease confined to a single lymph node region or lymphoid structure, or a single extranodal site (IE). Modifiers (all stages): A = no B symptoms; B = B symptoms (unexplained fever, drenching night sweats, or >10% body-weight loss); E = limited contiguous extension into one adjacent extranodal site; S = splenic involvement; X = bulky disease (mass >10 cm, or a mediastinal mass exceeding one-third of the internal transverse thoracic diameter).		Early-stage (I-II) favorable disease is treated with combined-modality therapy: a short course of ABVD chemotherapy (e.g. 2 cycles) followed by involved-site/involved-field radiotherapy.Early stage (I-IIA) carries an excellent prognosis, with roughly 90% 5-year overall survival.
okfonte
Wikipedia 'Ann Arbor staging', Principal stages (Stage I) + Modifiers (A/B, E, S, X). Management and survival from StatPearls NBK499969, Treatment/Prognosis ('two cycles of ABVD ... followed by ... involved-field radiation therapy'; early stages I-IIA ~90% 5-year overall survival).
II
Stage II
Involvement of two or more lymph node regions on the same side of the diaphragm (or localized contiguous extranodal extension, IIE).		Early-stage (I-II) disease is treated with combined-modality therapy (ABVD chemotherapy plus involved-site radiotherapy); unfavorable features (bulky/X disease, elevated ESR, extranodal extension) prompt more chemotherapy cycles (4-6) and higher-dose radiation.Early favorable stage I-IIA disease has roughly 90% 5-year overall survival; unfavorable features worsen the outlook.
okfonte
Wikipedia 'Ann Arbor staging', Principal stages (Stage II); corroborated by StatPearls NBK499969, Staging ('2 or more lymph node regions on the same side of the diaphragm'). Management/prognosis from NBK499969 Treatment (combined modality; 4-6 cycles for unfavorable features) and Prognosis (~90% early-stage OS).
III
Stage III
Lymph node regions or lymphoid structures involved on both sides of the diaphragm; may include splenic (S) or limited contiguous extranodal (E) involvement.		Advanced-stage disease is treated mainly with multi-agent chemotherapy (ABVD for most; escalated BEACOPP or Stanford V in selected higher-risk patients per IPS); radiotherapy is generally not beneficial.Advanced stage carries a less favorable prognosis than early stage; risk is further stratified by the International Prognostic Score.
okfonte
Wikipedia 'Ann Arbor staging', Principal stages (Stage III); corroborated by StatPearls NBK499969, Staging ('both sides of the diaphragm'). Management from NBK499969 Treatment (advanced-stage chemotherapy 'ABVD for most patients'; 'radiation, in general, is not beneficial'); IPS stratification noted.
IV
Stage IV
Diffuse or disseminated involvement of one or more extralymphatic (extranodal) organs or tissues (e.g. liver, bone marrow), beyond limited contiguous E-type extension, with or without associated nodal involvement.		Treated as advanced-stage disease with multi-agent chemotherapy (ABVD for most; escalated BEACOPP or Stanford V in selected higher-risk patients); radiotherapy is generally not beneficial.Most extensive stage with the least favorable outlook; stage IV disease has roughly 60% 5-year overall survival.
okfonte
Wikipedia 'Ann Arbor staging', Principal stages (Stage IV); corroborated by StatPearls NBK499969, Staging ('extranodal sites beyond those designated as E'). Management/prognosis from NBK499969 Treatment (advanced-stage chemotherapy) and Prognosis ('stage IV disease ... approximately 60%' 5-year OS).

Referências cruzadas

caracterizaDeauville 5PS. Deauville five-point FDG-PET scale for lymphomaDeauville assesses metabolic response within the Ann Arbor / Lugano staging framework.
fronteira compartilhadaLugano. Lugano classification for lymphoma responseThe Lugano classification refines Ann Arbor staging and response assessment for lymphoma.

Histórico de versões

Nenhum evento de versão registrado.

Quickstart da APIGET /api/v1/systems/ann-arboraberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/ann-arbor"
Ver documentação completa